457 |
Endeavor Clinical Program Overview |
Marco A. Costa |
Sep. 28. 07 |
456 |
Visionable Performance of Next Generation of DES |
Duncan Hung Kwong Ho |
Sep. 20. 07 |
455 |
The J-Cypher Registry Update |
Takeshi Kimura |
Sep. 20. 07 |
454 |
Is DES Deployment Technique Associated with Late Stent Thrombosis?; New Insights from the STLLR Trial |
Marco A. Costa |
Sep. 20. 07 |
453 |
Next Generation of DES |
Alexandre Abizaid |
Sep. 20. 07 |
452 |
Two-Year Follow Up of a First-in-Man Registry with a Bioabsorbable Polymer Based Sirolimus-Eluting Stent (Medistra Excel Drug-Eluting Stent Trial - MEDISTRA Study) |
Teguh Santoso |
Sep. 20. 07 |
451 |
Triple Antiplatelet Therapy After Drug-Eluting Stenting in Patients with High Risk of Restenosis |
Seong-Wook Park |
Sep. 14. 07 |
450 |
Taking the Evidence-Based Approach to ACS: Examination of New Antithrombin Trial Data |
Gregg W. Stone |
Sep. 14. 07 |
449 |
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High Risk PCI |
Charles A. Simonton |
Sep. 14. 07 |
448 |
Bivalirudin on Trial: Rationale and Status of ISAR-REACT 3 and 4 |
Adnan Kastrati |
Sep. 14. 07 |